Literature DB >> 28264840

Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.

Teclegiorgis Gebremariam1, Sondus Alkhazraji1, Clara Baldin1, Laura Kovanda2, Nathan P Wiederhold3, Ashraf S Ibrahim4,5.   

Abstract

We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Rhizopus delemar; isavuconazole; mucormycosis; murine; posaconazole; prophylaxis; voriconazole

Mesh：

Substances：

Year:  2017        PMID： 28264840      PMCID： PMC5404573          DOI： 10.1128/AAC.02589-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Zygomycosis: reemergence of an old pathogen.

Authors:  Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

2.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

3.  Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Authors:  Stéphane Vigouroux; Odile Morin; Philippe Moreau; Françoise Méchinaud; Nadine Morineau; Béatrice Mahé; Patrice Chevallier; Thierry Guillaume; Viviane Dubruille; Jean-Luc Harousseau; Noël Milpied
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

Review 4.  Healthcare-associated mucormycosis.

Authors:  Blandine Rammaert; Fanny Lanternier; Jean-Ralph Zahar; Eric Dannaoui; Marie-Elisabeth Bougnoux; Marc Lecuit; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

5.  Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Abdullah Alqarihi; Priya Uppuluri; Nkechi Azie; John E Edwards; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

6.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

7.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

8.  Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

Authors:  Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

9.  Invasive zygomycosis in India: experience in a tertiary care hospital.

Authors:  A Chakrabarti; S S Chatterjee; A Das; N Panda; M R Shivaprakash; A Kaur; S C Varma; S Singhi; A Bhansali; V Sakhuja
Journal:  Postgrad Med J       Date:  2009-11       Impact factor: 2.401

10.  A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Authors:  Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191
View more
  7 in total

1.  Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model.

Authors:  Thomas Brunet; Kévin Brunet; Grégory Jouvion; Estelle Cateau; Sandrine Marchand; Blandine Rammaert
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Lin Lin; Nathan P Wiederhold; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

4.  Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Abdullah Alqarihi; Nathan P Wiederhold; Laura K Najvar; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  J Fungi (Basel)       Date:  2021-04-18

5.  In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.

Authors:  Andrew M Borman; Mark Fraser; Zoe Patterson; Michael D Palmer; Elizabeth M Johnson
Journal:  J Fungi (Basel)       Date:  2021-04-02

Review 6.  Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.

Authors:  Omer Sefvan Janjua; Muhammad Saad Shaikh; Muhammad Amber Fareed; Sana Mehmood Qureshi; Muhammad Ikram Khan; Danya Hashem; Muhammad Sohail Zafar
Journal:  J Fungi (Basel)       Date:  2021-12-31

7.  Cutaneous and Pulmonary Mucormycosis in Rag1- and Il2rg-deficient Rats.

Authors:  Anna E Sarfaty; Susan R Compton; Peter C Smith; Caroline J Zeiss
Journal:  Comp Med       Date:  2020-07-31       Impact factor: 0.982
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.